e-Therapeutics plc
(the "Company")

Notification of Change of Interest in the Company's Share Capital

On 4 February 2008, the Company received notification that, following disposals of a total of 200,000 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares") between 28 January 2008 and 31 January 2008 (the individual disposals were: 100,000 Ordinary Shares on 28 January, 25,000 Ordinary Shares on both 29 and 30 January and 50,000 Ordinary Shares on 31 January), RAB Special Situations (Master) Fund Limited ("RAB") is the beneficial owner of 17,207,950 Ordinary Shares, representing 30.89 per cent. of the total number of Ordinary Shares and of the total voting rights of the Company. The registered holder of these Ordinary Shares is Credit Suisse Client Nominees (UK) Limited.

RAB has only disposed of a very small proportion of its Ordinary Shares and remains a strong supporter of the Company going forward.

For more information please contact:

John Cordiner, e-Therapeutics plc Tel: 0191 233 1317

Richard Lindley, WH Ireland Limited Tel: 0113 394 6628